Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has issued an update.
CSL Limited has declared an interim dividend of USD 1.30 per ordinary fully paid share, covering the six‑month period ended 31 December 2025. The dividend will trade ex‑dividend on 10 March 2026, with a record date of 11 March 2026 and payment scheduled for 9 April 2026, reinforcing the company’s ongoing capital returns to shareholders.
The announcement signals continued confidence in CSL’s cash generation and balance sheet strength, as the board maintains its practice of regular distributions despite a challenging global healthcare environment. Income‑focused investors in the biopharmaceutical group will closely watch how this payout fits into CSL’s broader capital allocation and growth investment plans over the current financial year.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$198.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a healthcare company listed on the ASX, with its ordinary fully paid shares trading under the ticker CSL. The group operates in the biopharmaceutical sector, focusing on innovative therapies and products that support patients globally and generate returns for shareholders in international markets.
Average Trading Volume: 920,389
Technical Sentiment Signal: Sell
Current Market Cap: A$87.57B
Learn more about CSL stock on TipRanks’ Stock Analysis page.